Morgan Stanley Infla Rx N.V. Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in Infla Rx N.V. stock. As of the latest transaction made, Morgan Stanley holds 978,521 shares of IFRX stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
978,521
Previous 922,821
6.04%
Holding current value
$1.6 Million
Previous $1.5 Million
0.13%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding IFRX
# of Institutions
40Shares Held
13.8MCall Options Held
12.9KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY5.73MShares$9.4 Million0.38% of portfolio
-
Eversept Partners, LP New York, NY1.31MShares$2.14 Million0.15% of portfolio
-
Citigroup Inc1.2MShares$1.97 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY870KShares$1.43 Million0.11% of portfolio
-
Tang Capital Management LLC San Diego, CA769KShares$1.26 Million0.14% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $72.5M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...